Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9972730 | 0.90 | SMN1; SMN2 (0.44) | SMN1; SMN2FFAR1FFAR4CNR2CNR1 | |
| SCHEMBL3762438 | 0.88 | ALOX5 (0.50) | ALOX5SCN9A | |
| SCHEMBL3762026 | 0.81 | KCNA3 (0.36) | SMN1; SMN2 | |
| SCHEMBL3757784 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2FFAR1FFAR4CNR2CNR1 | |
| SCHEMBL3767783 | 0.79 | KCNA2 (0.39) | CNR2CNR1 | |
| SCHEMBL3761768 | 0.77 | SMN1; SMN2 (0.40) | PTGS1PTGS2SMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL3386404 | 0.76 | SMN1; SMN2 (0.41) | PTGS1PTGS2SMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL3754114 | 0.76 | KCNA3 (0.41) | SMN1; SMN2SCN9A | |
| SCHEMBL3392778 | 0.76 | SMN1; SMN2 (0.46) | SMN1; SMN2 | |
| SCHEMBL1542014 | 0.76 | PDE4D (0.48) | ALOX5SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
| WO-2009043117-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNH3 | MET 4831/4885PTGS1 2500/4885PTGS2 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.